Positive results for BioVie’s Parkinson’s and Alzheimer’s phase 2 trials
December 6, 2022Research and Development
BioVie has announced positive results from two phase 2 trials which have been assessing NE3107’s efficacy in treating Parkinson’s Disease …
Nkarta data supports natural killer cells in cancer treatment
December 6, 2022Research and Development
San Francisco, US-based Nkarta have been assessing the power of natural killer (NK) cells in oncology treatments. The treatment is …
Aptamer Group sign deals to develop Optimer solutions
December 5, 2022Business Services
Aptamer Group has announced a selection of contracts aimed at exploring Optimer technology, which will offer new strategies for therapeutics …
Innovent Biologics and UNION Therapeutics announce first dosing of Chinese subject in phase 1 study
December 5, 2022Research and Development
Innovent Biologics, a biopharmaceutical company which develops, manufactures and commercialises medicines for the treatment of illnesses within the scope of …
Amgen’s obesity drug appears promising with few side effects
December 5, 2022Research and Development
Amgen Inc’s new obesity drug has appeared promising in its small phase 1 trial, meaning they will be able to …
New insights into HIV vaccine revealed by researchers
December 5, 2022Research and Development
Although researchers have previously always struggled to develop an efficient HIV vaccine, the results of a first-in-human clinical trial for …
Scottish Medicines Consortium approves Bayer’s Kerendia for NHS Scotland
December 2, 2022Medical Communications
The Scottish Medicines Consortium (SMC) has given the green light to Bayer’s Kerendia (finerenone), a chronic kidney disease (CKD) drug …
GSK’s two new cancer drugs look promising
December 2, 2022Research and Development
GlaxoSmithKline (GSK) appear to be making some positive progress in their oncology department, with drugs for both myelofibrosis and endometrial …
AstraZeneca and MSD launch prostate cancer awareness campaign
December 2, 2022Medical Communications
AstraZeneca and MSD (known as Merck & Co. in the United States and Canada) have announced their collaborative global prostate …
FDA grants approval to WISE for neuromonitoring cortical strip
December 2, 2022Medical Communications
WISE, a medical equipment manufacturer based in Italy, has obtained FDA approval for its single-use medical device WISE Cortical Strip …
Eli Lilly’s COVID-19 drug bebtelovimab loses FDA authorisation
December 1, 2022Manufacturing and Production
The FDA have announced that Eli Lilly’s COVID-19 drug bebtelovimab is not authorised for emergency use in the US, as …
Pulmonx secure Japanese approval for Zephyr Valve for COPD/emphysema
December 1, 2022Medical Communications
Pulmonx, a US-based medical technology company, has secured approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for …
FDA approves Ferring’s first-in-class microbiota-based live biotherapeutic
December 1, 2022Medical Communications
Switzerland-based Ferring Pharmaceuticals announced the FDA has approved its biotherapeutic REBYOTA®, indicated for the prevention of recurrence of Clostridioides difficile …
Elon Musk’s Neuralink to conduct human trials in 2023
December 1, 2022Research and Development
Neuralink owner Elon Musk announced that he has submitted paperwork to the FDA which he hopes will allow Neuralink to …
Stem cell transplants could be offered to MS patients in new trial
November 30, 2022Research and Development
In a world-first trial, the University of Sheffield and Sheffield Teaching Hospital NHS Foundation Trust will investigate the efficacy of …
Collaboration between BioNTech and Ryvu Therapeutics to develop and commercialise immuno-modulatory small molecule candidates
November 30, 2022Research and Development
Ryvu Therapeutics, a clinical-stage oncology therapeutics development company, has announced a collaboration with BioNTech, which will consist of two parts: …
New Alzheimer’s drug, lecanemab slows disease but divides opinions
November 30, 2022Research and Development
Japanese drugmaker Eisai and its US partner Biogen have announced that their new drug to treat Alzheimer’s disease appeared to …
RadNet’s Aidence AI subsidiary and Google Health enter into agreement to bring lung cancer screening model to market
November 30, 2022Research and Development
Aidence, an AI subsidiary of RadNet which looks at lung health, has partnered with Google Health to license Google Health’s …
Peter Williams
November 29, 2022Business Services
Incyte has announced its appointment of Peter Williams as General Manager for the UK and Ireland division. His new role …
University of Texas and Novartis Pharmaceuticals develop new computer platform for easier drug discovery
November 29, 2022Research and Development
Researchers from both the University of Texas, US and Novartis Pharmaceuticals have developed a computer-based platform which appears to make …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
